White House Reverses Course, Approves New FDA COVID-19 Vaccine Guidelines Published: Oct. 7, 2020 By Alex Keown BioSpace   The White House has reversed its position on new vaccine guidelines proposed by the U.S. Food and Drug Administration. The approval of the new guidelines all but assures that a vaccine for the novel coronavirus that has […]

President Donald Trump signed a new executive order aimed at lowering drug prices in the United States by linking them to those of other nations and expanding the scope of a July 2020 action.

In an aim to create a strong domestic supply chain, President Donald Trump signed an Executive Order that calls for federal agencies to purchase “essential drugs” and medical supplies that are produced in the United States, rather than from abroad as is the current practice.

A meeting with top pharmaceutical executives that President Donald Trump promised wasn called off, a White House official said.

As the number of diagnosed cases of COVID-19 continues to increase across the globe and more and more governments are urging citizens to self-quarantine, the pharmaceutical and life sciences industry continues to work toward the development of a vaccine and therapies for the respiratory infection that was declared a pandemic by the World Health Organization.

The Trump administration secured commitments from top pharmaceutical companies to work together to develop a vaccine and treatments to fight the coronavirus.

As the J.P. Morgan Healthcare Conference continues to roll on with companies showcasing their pipelines and business plans, negative reports about the host city San Francisco have been made.

According to the Pharmaceutical Research and Manufacturers of America (PhRMA), there are 264 vaccines in development to prevent and treat diseases.

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

PhRMA CEO Stephen Ubl said House Speaker Nancy Pelosi’s plan would be “devastating” to the industry.